Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Healthcare Reform Proposals Expected No Sooner Than Fall
February 26, 2001
- Welfide Licenses Agent for Diabetic Neuropathy to Takeda
February 26, 2001
- Additional Indications Required to Commercialize Artificial Erythrocytes
February 26, 2001
- Fujisawa Launches Protopic in US
February 26, 2001
- Aventis Behring Launches Web Site
February 26, 2001
- Worldwide Sales of Yakult's Irinotecan to Top \150 Bil. in 2005
February 26, 2001
- Council Starts Discussions to Improve Drug Information Supply System
February 26, 2001
- Kyorin, Ono to Codevelop Drug for Urinary Incontinence
February 26, 2001
- METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
- BUSINESS NEWS IN BRIEF -1-
February 26, 2001
- Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
- REGULATORY NEWS IN BRIEF
February 26, 2001
- WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
- New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
- Kirin to Sponsor Genomic Medical Engineering Course at Tottori Univ.
February 26, 2001
- New ARIA Guidelines Prepared by WHO for Allergic Rhinitis
February 26, 2001
- Delisting Should Be Considered for Certain Drugs: Finance Ministry Officer
February 19, 2001
- Nihon Nosan Kogyo Forms Alliance with PPL Therapeutics of UK for Genomic Technology
February 19, 2001
- Japan, EU Mutual GMP Recognition Coming Soon
February 19, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…